Blurred Lines: Can Providers Become Drug Manufacturers?

Posted by Pratap Khedkar on Fri, Jan 26, 2018

Bill Coyle and Paul Darling co-authored this blog post with Pratap Khedkar.

The healthcare world had barely thought through the potential effects of the CVS/Aetna merger when news broke of another deal aiming to blur healthcare’s established business models: Four provider networks announced a nonprofit collaboration to manufacture generic drugs to keep prices down and lessen shortages. Skeptics have already pointed to considerable regulatory and manufacturing hurdles, so let’s focus on strategy and not implementation. If this DIY drug supply does start flowing, will it have its intended impact?


>
Read More

Faster, Smarter, More Agile: How to Sell in Pharma When Doctors Become Employees

Posted by Jude Konzelmann on Tue, Nov 19, 2013

Single-physician and small-group practices aren’t going away entirely, but each year, more doctors merge into large group practices. Some will form enormous, multi-specialty practices, and in many cases, these group practices are integrating with hospital systems to form networks across settings of care.

The one-to-one selling approach to doctors that the industry has used for decades isn’t completely dead. But that approach is no longer as impactful as it was in the past, when practitioners had more significant influence on drug usage. The question on the mind of most biopharma sales leaders today is this:  How can our sales force interact with these new physician practices and health networks in which physicians are employees?


>
Read More